The performance of companies tied to flagship drugs like Viagra presents a nuanced investment scenario . While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the expiry in key regions has introduced significant risk . Investors are now facing the effect of generic competition , diminishing r